YUTIQ
Eyepoint Pharmaceuticals Us, Inc.
Application Filed: 2016-11-29
Trademark Application Details
REGISTERED
| Research |
OneLook
Acronym Finder
|
| Serial Number | 87250580 |
| Registration Number | 5763976 |
| Mark Drawing Code | 4000: Illustration: Drawing with word(s)/letter(s)/number(s) in Block form |
| Attorney Name | Jenevieve Maerker, Esq. |
| Attorney Docket Number | 32265.00005 |
| Law Office Assigned | M30 |
| Employee Name | TAYLOR, DAVID T |
Timeline
| 2016-11-29 | Application Filed |
| 2017-04-18 | Published for Opposition |
| 2019-02-01 | Date of First Use |
| 2019-05-28 | Status: Live/Registered |
| 2019-05-28 | Trademark Registered |
| 2019-07-01 | Location: TMO LAW OFFICE 112 |
| 2019-11-27 | Transaction Date |
Trademark Applicants & Owners
| Owner: |  EYEPOINT PHARMACEUTICALS US, INC. |
| Address | 480 PLEASANT STREET, SUITE B300 WATERTOWN DE 02472 |
| Legal Entity Type | Corporation |
| Legal Entity State | DE |
Documents
Click the blue "Refresh" button to load certificates, specimines, application, and other documents.
Attorney of Record
Good, Services, and Codes
| International Codes: | 5 |
| U.S. Codes: | 006,018,044,046,051,052 |
| International Codes: | 10 |
| U.S. Codes: | 026,039,044 |
| Type Code | Type |
|---|---|
| GS0051 | Drug delivery agents consisting of polymer compounds that facilitate the delivery of pharmaceuticals for the treatment of ocular diseases and conditions, namely, uveitis, retinal vein occlusion, macular edema, macular disease, retinal disease, and glaucoma; pharmaceutical preparations for the treatment of ocular diseases and conditions, namely, uveitis, retinal vein occlusion, macular edema, macular disease, age-related macular degeneration, retinal disease, and glaucoma |
| A00001 | In the statement, lines 4-9, is deleted, and "CLASS 5: Drug delivery agents consisting of polymer compounds that facilitate the delivery of pharmaceuticals for the treatment of ocular diseases and conditions, namely, uveitis and retinal disease; pharmaceutical preparations for the treatment of ocular diseases and conditions, namely, uveitis and retinal disease" is inserted. |
Trademark Filing History
| Description | Date | Event Coding |
|---|---|---|
| NEW APPLICATION ENTERED IN TRAM | 2016-12-02 | 1 NWAP I:Incoming Correspondence |
| NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 2016-12-05 | 2 NWOS I:Incoming Correspondence |
| TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | 2016-12-08 | 3 REAP I:Incoming Correspondence |
| ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | 2016-12-08 | 4 ARAA I:Incoming Correspondence |
| ASSIGNED TO EXAMINER | 2017-03-03 | 5 DOCK D:Assigned to Examiner |
| APPROVED FOR PUB - PRINCIPAL REGISTER | 2017-03-04 | 6 CNSA P: |
| NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | 2017-03-29 | 7 NONP E:E-Mail |
| PUBLISHED FOR OPPOSITION | 2017-04-18 | 8 PUBO A:Allowance for Publication |
| OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | 2017-04-18 | 9 NPUB E:E-Mail |
| NOA E-MAILED - SOU REQUIRED FROM APPLICANT | 2017-06-13 | 10 NOAM E:E-Mail |
| TEAS EXTENSION RECEIVED | 2017-09-04 | 11 EEXT I:Incoming Correspondence |
| EXTENSION 1 FILED | 2017-09-04 | 12 EXT1 S: |
| EXTENSION 1 GRANTED | 2017-09-04 | 13 EX1G S: |
| NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2017-09-06 | 14 EXRA E:E-Mail |
| AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | 2018-04-18 | 15 ASGN I:Incoming Correspondence |
| TEAS EXTENSION RECEIVED | 2018-05-10 | 16 EEXT I:Incoming Correspondence |
| EXTENSION 2 FILED | 2018-05-10 | 17 EXT2 S: |
| EXTENSION 2 GRANTED | 2018-05-10 | 18 EX2G S: |
| NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2018-05-12 | 19 EXRA E:E-Mail |
| TEAS EXTENSION RECEIVED | 2018-11-09 | 20 EEXT I:Incoming Correspondence |
| EXTENSION 3 FILED | 2018-11-09 | 21 EXT3 S: |
| EXTENSION 3 GRANTED | 2018-11-09 | 22 EX3G S: |
| NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2018-11-13 | 23 EXRA E:E-Mail |
| TEAS STATEMENT OF USE RECEIVED | 2019-03-12 | 24 EISU I:Incoming Correspondence |
| CASE ASSIGNED TO INTENT TO USE PARALEGAL | 2019-03-27 | 25 AITU A:Allowance for Publication |
| USE AMENDMENT FILED | 2019-03-12 | 26 IUAF S: |
| STATEMENT OF USE PROCESSING COMPLETE | 2019-03-27 | 27 SUPC I:Incoming Correspondence |
| ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | 2019-04-22 | 28 CNPR P: |
| NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | 2019-04-23 | 29 SUNA E:E-Mail |
| REGISTERED-PRINCIPAL REGISTER | 2019-05-28 | 30 R.PR A:Allowance for Publication |
| TEAS SECTION 7 REQUEST RECEIVED | 2019-06-13 | 31 ES7R I:Incoming Correspondence |
| CASE ASSIGNED TO POST REGISTRATION PARALEGAL | 2019-06-28 | 32 APRE A:Allowance for Publication |
| AMENDMENT UNDER SECTION 7 - ISSUED | 2019-07-01 | 33 A7OK O:Outgoing Correspondence |
| TEAS CHANGE OF OWNER ADDRESS RECEIVED | 2020-10-28 | 34 COAR I:Incoming Correspondence |
| TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | 2020-10-28 | 35 REAP I:Incoming Correspondence |
| ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | 2020-10-28 | 36 ARAA I:Incoming Correspondence |
| TEAS CHANGE OF CORRESPONDENCE RECEIVED | 2020-10-28 | 37 TCCA I:Incoming Correspondence |
| APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | 2020-10-28 | 38 CHAN I:Incoming Correspondence |
| AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | 2023-06-21 | 39 ASGN I:Incoming Correspondence |
| TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | 2023-06-20 | 40 REAP I:Incoming Correspondence |
| ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | 2023-06-20 | 41 ARAA I:Incoming Correspondence |
| TEAS CHANGE OF CORRESPONDENCE RECEIVED | 2023-06-20 | 42 TCCA I:Incoming Correspondence |
Similar Marks
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
 YUTIQ 88167946 not registered Live/Pending |
EyePoint Pharmaceuticals US, Inc. 2018-10-24 |
 YUTIQ 87250580 5763976 Live/Registered |
EYEPOINT PHARMACEUTICALS US, INC. 2016-11-29 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 